These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 12595914)

  • 1. Enrasentan, an antagonist of endothelin receptors.
    Cosenzi A
    Cardiovasc Drug Rev; 2003; 21(1):1-16. PubMed ID: 12595914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antihypertensive treatment with enrasentan (SB217242) in an animal model of hypertension and hyperinsulinemia.
    Cosenzi A; Bernobich E; Bonavita M; Bertola G; Trevisan R; Bellini G
    J Cardiovasc Pharmacol; 2002 Apr; 39(4):488-95. PubMed ID: 11904522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enrasentan improves survival, limits left ventricular remodeling, and preserves myocardial performance in hypertensive cardiac hypertrophy and dysfunction.
    Willette RN; Anderson KM; Nelson AH; Olzinski AR; Woods T; Coatney RW; Aiyar N; Ohlstein EH; Barone FC
    J Cardiovasc Pharmacol; 2001 Oct; 38(4):606-17. PubMed ID: 11588531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic potential for endothelin receptor antagonists in cardiovascular disorders.
    Spieker LE; Noll G; Lüscher TF
    Am J Cardiovasc Drugs; 2001; 1(4):293-303. PubMed ID: 14728028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonpeptide endothelin receptor antagonists. VI: Pharmacological characterization of SB 217242, a potent and highly bioavailable endothelin receptor antagonist.
    Ohlstein EH; Nambi P; Lago A; Hay DW; Beck G; Fong KL; Eddy EP; Smith P; Ellens H; Elliott JD
    J Pharmacol Exp Ther; 1996 Feb; 276(2):609-15. PubMed ID: 8632328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of endothelin in the control of peripheral vascular tone in human hypertension.
    Taddei S; Virdis A; Ghiadoni L; Sudano I; Magagna A; Salvetti A
    Heart Fail Rev; 2001 Dec; 6(4):277-85. PubMed ID: 11447302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelin and endothelin antagonists: pharmacology and clinical implications.
    Lüscher TF; Wenzel RR
    Agents Actions Suppl; 1995; 45():237-53. PubMed ID: 7717186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelin-1 and the regulation of vascular tone.
    La M; Reid JJ
    Clin Exp Pharmacol Physiol; 1995 May; 22(5):315-23. PubMed ID: 7554421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unmasking of endothelin-1-induced natriuresis and renal vasodilation in the dog by enrasentan (SB 217242).
    Brooks DP; DePalma PD
    J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S346-7. PubMed ID: 11078416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma- and cerebrospinal fluid-immunoreactive endothelin-1: effects of nonpeptide endothelin receptor antagonists with diverse affinity profiles for endothelin-A and endothelin-B receptors.
    Willette RN; Sauermelch CF; Storer BL; Guiney S; Luengo JI; Xiang JN; Elliott JD; Ohlstein EH
    J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S149-57. PubMed ID: 9595425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of endothelin B (ETB) receptors in rabbit isolated pulmonary artery and bronchus.
    Hay DW; Luttmann MA; Beck G; Ohlstein EH
    Br J Pharmacol; 1996 Jul; 118(5):1209-17. PubMed ID: 8818345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endothelin as a regulator of cardiovascular function in health and disease.
    Haynes WG; Webb DJ
    J Hypertens; 1998 Aug; 16(8):1081-98. PubMed ID: 9794709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelin in neurohormonal activation in heart failure.
    Boerrigter G; Burnett JC
    Coron Artery Dis; 2003 Nov; 14(7):495-500. PubMed ID: 14561942
    [No Abstract]   [Full Text] [Related]  

  • 14. New developments in heart failure: role of endothelin and the use of endothelin receptor antagonists.
    Suresh DP; Lamba S; Abraham WT
    J Card Fail; 2000 Dec; 6(4):359-68. PubMed ID: 11145761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelin and endothelin antagonists in hypertension.
    Schiffrin EL
    J Hypertens; 1998 Dec; 16(12 Pt 2):1891-5. PubMed ID: 9886874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highlights on endothelins: a review.
    Ortega Mateo A; de Artiñano AA
    Pharmacol Res; 1997 Nov; 36(5):339-51. PubMed ID: 9441724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recently discovered sulfonamide-, acyl sulfonamide- and carboxylic acid-based endothelin antagonists.
    Wu C; Holland GW; Brock TA; Dixon RA
    IDrugs; 2003 Mar; 6(3):232-9. PubMed ID: 12789612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelin: role in hypertension.
    Schiffrin EL
    Biol Res; 1998; 31(3):199-208. PubMed ID: 9830507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelin antagonists.
    Benigni A; Remuzzi G
    Lancet; 1999 Jan; 353(9147):133-8. PubMed ID: 10023915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endothelin in the pulmonary circulation with special reference to hypoxic pulmonary vasoconstriction.
    Holm P
    Scand Cardiovasc J Suppl; 1997; 46():1-40. PubMed ID: 9265559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.